Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > PFE to acquire Seagen?

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Feb 27, 2023 1:13pm

87 Views

Post# 35307515

RE:RE:RE:PFE to acquire Seagen?

And the reason that Merck stepped down from its intention to acquire Segean is that in September 2022 judgement Google lost its challenge of the EU's antitrust decision.

"The judgment strengthens the hand of the Commission. It confirms the Commission can use antitrust proceedings as a backstop threat to enforce rapid compliance ..."

https://www.reuters.com/technology/eu-courts-wed-ruling-record-44-bln-google-fine-may-set-precedent-2022-09-14/

<< Previous

Bullboard Posts

Next >>

Morning Market Outlook for July 8, 2024